Synercid

Synercid is approved for the treatment of complicated skin and soft tissue infections caused by certain Gram-positive bacteria. Additionally, the Infectious Diseases Society of America (IDSA) has suggested that Synercid may be an option for the treatment of certain infections in the brain that can't be treated with other antibiotics. Although it isn't FDA approved for this purpose, professional organizations like the IDSA have recommended it based on clinical evidence.

Synercid can treat skin infections caused by certain bacteria species called Staphylococcus aureus and Streptococcus pyogenes. It's also typically used for people who are confirmed to have a severe (or complicated) skin infection from resistant bacteria that will respond to Synercid or in people with allergies to penicillin antibiotics. Synercid isn't used often, because other newer antibiotics may have fewer interactions with medications and potentially lower cost than Synercid.

Synercid is a combination of two antibiotics. Quinupristin and dalfopristin both block the bacteria from making important proteins for growth and sustaining life. This causes the bacteria to be unable to survive.

Synercid is typically given as an injection through the veins (intravenously or IV) by a healthcare provider in the hospital. Each infusion takes about 1 hour.

The dose will depend on your body weight. The typical dose in adults and children 12 years or older is 7.5 mg/kg of body weight given through the veins (intravenously or IV) every 12 hours. The typical length of treatment for complicated skin and soft tissue infections is 7 days, but your provider might extend this to a longer period of time depending on how your infection is responding to the medication.